Evaluation of the Vasoconstriction Properties of MC2-01 Cream

Inclusion Criteria

• Male or female subjects aged 18 years to 50 years old having signed and dated an informed consent,
• Non-smoker subjects,
• Subjects demonstrating adequate vasoconstriction to Diprolene® cream within 15 days prior to dosing (unoccluded application of Diprolene® cream for 4-6 hours must show a visual score of skin blanching of at least one unit (visual scale (0-4)),
• Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn),
• Female subjects of non-childbearing potential defined as surgically sterile or post-menopausal (at least one year post cessation of menses),
• Female subjects of childbearing potential who have been, in the opinion of the Investigator, using an approved method of birth control (e.g. oral contraception pill or patch, intra-uterine devices, contraceptive implants or vaginal rings, condoms, bilateral tubal ligation) at trial entry and agree to continue until the end of the last trial visit,
• Female subjects of childbearing potential must have a negative urine pregnancy test at screening visit and at Day 1 to continue,
• Subjects willing and able to follow all the trial procedures and complete the whole trial,
• Subjects affiliated to a social security system.

Exclusion Criteria

• Female subjects who are breastfeeding,
• Use of topical corticosteroids on the test areas (forearms) within 4 weeks prior to the screening phase,
• Use of systemic drugs which may interfere with the blanching reaction including, but not limited to, corticosteroids and other vasoactive drugs (nitrates derivatives, antihypertensive, phenylpropanolamine, diphenhydramine, pseudo-ephedrine, antihistamines, non-steroidal anti-inflammatory drug and aspirin/acetylsalicylic acid), within two weeks prior to screening visit,
• Use of any other medication would interfere with the trial results, in particular topical drugs applied on the test area within two weeks prior to screening visit,
• Subjects having a caffeine (i.e. coffee, cola, soft-drinks containing caffeine) intake greater than 500mg per day (1 cup of coffee contains approximately 85mg of caffeine) within one day prior to screening visit and until the end of the last visit of the test phase,
• Subjects with a history of drug or alcohol abuse/addiction.
• Abnormal pigmentation of the skin or skin type, that could, in any way, confound interpretation of the trail results (skin type V to VI on the Fitzpatrick scale),
• Subjects with obvious difference in skin color between arms,
• Subjects with any of the following conditions present on the test areas: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, atrophic skin, and striae atrophicae, fragility of skin veins, ichthyosis and ulcers,
• Any current systemic or cutaneous disease that could in any way confound interpretation of the trial results (e.g. atopic dermatitis, contact eczema, or psoriasis),
• Known or suspected hypersensitivity to any component(s) of Investigational Medical Product (IMP),
• Subjects with current participation in any other interventional clinical, based on interview of the subject,
• Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the last 4 weeks prior to screening phase,
• Previously enrolled in this clinical trial,
• Subjects who do not accept to avoid strenuous physical activity nor alcohol intake during the study.
• In the opinion of the (sub)investigator, subjects who are unlikely to comply with the Clinical Trial Protocol (e.g. alcoholism, drug dependency or psychotic state),
• Subjects in close affiliation with the trial personnel (e.g. immediate family member or subordinate), subjects being a member of the clinical trial personnel, or being an employe